力诺药包：双主业发力+多维度投资打开增长空间

Core Viewpoint - Linuo Pharmaceutical Packaging (301188.SZ) is actively expanding its dual main businesses of pharmaceutical packaging glass and heat-resistant glass, while also disclosing multiple investment plans to support long-term development [1][4]. Group 1: Business Operations - Linuo Pharmaceutical Packaging focuses on the research, production, and sales of borosilicate glass, with key products including medium borosilicate pharmaceutical glass and high borosilicate heat-resistant glass, primarily used in pharmaceutical packaging and consumer goods [2]. - In the first half of 2025, the company achieved a revenue of 499 million yuan and a net profit of 40.97 million yuan, with total assets reaching 2.537 billion yuan, reflecting a year-on-year growth of 7.67% [4]. - The company is enhancing its production capacity for pharmaceutical glass, with the first kiln of the "Lightweight Pharmaceutical Molded Glass Bottle (Class I) Industrialization Project" ignited and operational since February [4]. - Linuo Pharmaceutical Packaging is also investing in high-quality enterprises in the pharmaceutical packaging sector to broaden its product range and facilitate one-stop procurement for pharmaceutical clients [4]. Group 2: Strategic Initiatives - The company has established an e-commerce subsidiary in Hangzhou to promote its own brands "LEBOLEBO" and "brohouse," while transitioning from an OEM model to an ODM model to better meet the needs of younger consumers [4]. - Starting in 2024, Linuo Pharmaceutical Packaging is focusing on global expansion, conducting assessments in regions such as Saudi Arabia, Brazil, and Southeast Asia, and has signed a cooperation investment agreement with SANTISA LABORATóRIO FARMACêUTICO S/A [6]. - The company plans to establish a "Science and Technology Innovation Center and Supporting Facilities Project" and expand its product categories, with a joint investment of 92.65 million yuan with its controlling shareholder, Linuo Group, to set up Linuo Innovation Technology (Shanghe) Co., Ltd. [6]. Group 3: Acquisitions and Growth - The board of directors approved the acquisition of a 30% stake in Suzhou Chuangyang New Materials Technology Co., Ltd. for 84 million yuan, which specializes in pharmaceutical packaging materials [7]. - The acquisition is expected to enhance Linuo Pharmaceutical Packaging's product offerings by integrating plastic packaging capabilities with its existing glass packaging, thereby providing a comprehensive "glass + plastic" service to mainstream pharmaceutical companies [7].